• Citer

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

par Strumberg, Dirk;Awada, Ahmad ;Hirte, Hal W;Clark, J W;Seeber, Siegfried;Piccart, P;Hofstra, E;Voliotis, Dimitris;Christensen, O;Brueckner, A;Schwartz, Brian
Référence European journal of cancer, 42, 4, page (548-556)
Publication Publié, 2006-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Auteur:	Strumberg, Dirk; Awada, Ahmad; Hirte, Hal W; Clark, J W; Seeber, Siegfried; Piccart, P; Hofstra, E; Voliotis, Dimitris; Christensen, O; Brueckner, A; Schwartz, Brian
Informations sur la publication:	European journal of cancer, 42, 4, page (548-556)
Statut de publication:	Publié, 2006-03
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	BAY 43-9006
	PDGFR inhibitor
	Phase I studies
	Pooled analysis
	Raf kinase inhibition
	Refractory solid tumours
	Sorafenib
	VEGFR inhibitor
MeSH keywords:	Administration, Oral
	Adolescent
	Adult
	Aged
	Antineoplastic Agents -- adverse effects
	Benzenesulfonates -- administration & dosage
	Benzenesulfonates -- adverse effects
	Clinical Trials, Phase I as Topic
	Dose-Response Relationship, Drug
	Drug Eruptions -- etiology
	Exanthema -- chemically induced
	Female
	Humans
	Male
	Maximum Tolerated Dose
	Middle Aged
	Neoplasms -- drug therapy
	Pyridines -- administration & dosage
	Pyridines -- adverse effects
	Treatment Outcome
Note générale:	Journal Article
	Meta-Analysis
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2005.11.014
	info:pii/S0959-8049(05)01070-1
	info:scp/32444439875
	info:pmid/16426838